IMR Press / CEOG / Volume 35 / Issue 3 / pii/1630638708775-1638170957

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Editorial
Action of progesterone receptor modulators on uterine leiomyomas
Show Less
1 Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe (Japan)
Clin. Exp. Obstet. Gynecol. 2008, 35(3), 165–166;
Published: 10 September 2008
Abstract

Novel progesterone receptor modulators (PRMs) have recently been demonstrated to be effective in the treatment of patients with symptomatic uterine leiomyomata. PRMs are shown to reduce leiomyoma size and improve leiomyoma-associated symptoms. However, the precise mechanisms underlying the action of PRMs remain to be elucidated. My co-workers and I have investigated in vitro action of PRMs in cultured leiomyoma cells and revealed that PRMs inhibit cell proliferation and induce apoptosis of leiomyoma cells. Moreover, our recent studies show that PRMs can modulate the metabolism of extracellular matrix proteins in cultured leiomyoma cells toward the collagenolysis. The update about an action of PRMs in uterine leiomyoma cells in vitro is described in this article.
Keywords
Progesterone receptor modulator
Leiomyoma
Proliferation
Apoptosis
Angiogenesis
Extracellular matrix
Share
Back to top